Cardiopulmonary bypass does not affect plasma concentration of preoperatively administered gabapentin

Abstract

Purpose: Drug effects can be unpredictable during cardiac surgery due to factors that may influence drug concentration, such as extracorporeal oxygenation and hemodilution. The primary aim of the current investigation was to determine whether plasma gabapentin concentration is altered by cardiopulmonary bypass (CPB). Methods: Following approval from the Research Ethics Board and written informed consent, we conducted this open-label prospective cohort investigation. A convenience sample of 16 patients, who were scheduled for coronary bypass surgery, received oral gabapentin 600 mg as follows: 90 min prior to induction of anesthesia, following tracheal extubation, and then every eight hours for a total of four doses. Plasma gabapentin concentration, as well as pain and sedation scores, were documented. Results: Plasma gabapentin concentrations were unaltered during CPB (31.9 ± 12.7 μmol·L-1 prior to CPB, 35.6 ± 12.9 to 37.2 ± 9.6 μmol·L-1 during CPB). However, using the current protocol, drug accumulation (reflected by increased drug concentrations) was observed following the third (58.2 ± 19.5 μmol·L-1) and the fourth (71.9 ± 34.3 μmol·L-1) doses. Pain and sedation scores and opioid requirements were comparable with those found in other studies. Conclusion: Plasma gabapentin concentration is unaltered during CPB following preoperative administration. Drug accumulation following third and fourth postoperative doses suggests the need for therapeutic drug monitoring in future trials. Gabapentin is well established as an effective adjunct analgesic in a number of surgical settings. Randomized controlled trials are necessary to evaluate analgesic efficacy, optimal dosing, and adverse effects in the setting of cardiac surgery. (ClinicalTrials.gov number, NCT01022736). © Canadian Anesthesiologists' Society 2010.